Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Haemophilia Stories

2012-04-16 10:24:04

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve...

2012-04-16 10:23:58

MONTREAL, April 16, 2012 /PRNewswire/ -- An estimated one in 1,000 women and men has a bleeding disorder. However, 75 percent still receive very inadequate treatment or no treatment at all. What will it take to Close the Gap? To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/world-hemophilia-day----april-17-147623835.html On World Hemophilia Day 2012, the global bleeding disorders community will spread the message to "Close the...

2012-04-03 06:26:04

MIDLOTHIAN, Va., April 3, 2012 /PRNewswire-USNewswire/ -- Patient Services, Inc. (PSI), the "ground breaking" 501(c)(3) non-profit, charitable organization of its kind transitioned the bleeding disorders Patient Services Items program (PSIp) to the Hemophilia Federation of America's (HFA) long-time program, Helping Hands Emergency Assistance effective April 3, 2012. (Logo: http://photos.prnewswire.com/prnh/20120214/MM53649LOGO ) Since July 2003, PSI has had the privilege...

2012-03-30 10:22:19

KING OF PRUSSIA, Pa., March 30, 2012 /PRNewswire/ -- CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo. CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL), is developing rVIIa-FP, a novel therapy to treat hemophilia A and hemophilia B patients who have...

2012-02-24 13:00:00

VIENNA, Feb. 24, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program. The CSL Behring rFVIII, called 'rVIII-SingleChain', is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL). "CSL is advancing at a very encouraging rate with...

2012-02-23 06:30:00

NES-ZIONA, Israel, Feb. 23, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that PROLOR scientist Dr. Gili Hart will present data on its long-acting clotting factors in preclinical development for the treatment of hemophilia at the European Association for Haemophilia and Allied Disorders (EAHAD) 5th Annual Congress. Dr. Hart's presentation, "FVIIa-CTP and FIX-CTP, novel long-acting coagulation factors with prolonged hemostatic effect and improved recovery in...

2012-02-22 07:30:00

ROME, Feb. 22, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced clinical results for the Company's lead product candidate, an intravenous recombinant factor IX (FIX) product being investigated for the treatment and prevention of bleeding in individuals with hemophilia B. The data demonstrated that Inspiration's FIX product provided effective surgical hemostasis in people with hemophilia B undergoing major surgical procedures. The data were highlighted...

2012-02-16 07:00:00

KING OF PRUSSIA, Pa., Feb. 16, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX. CSL Behring is...

2012-02-14 06:30:00

NES-ZIONA, Israel, Feb. 14, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice. The study was designed to measure the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP when compared with commercially available recombinant Factor VIIa. In vivo recovery is a pharmacokinetic...

2012-02-02 08:45:00

ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire/ -- CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B. Results of the study, which were presented during an oral session at the Gesellscaft fur Thrombose- und Hameostasegorschung (GTH) congress in Switzerland, showed that rIX-FP was well tolerated in all patients and lasted longer in the...